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whether or not there is evidence of regression, in comparison to the
control group that was not treated with statins?
Dr Brooke. The technical details of the operation were at the
discretion of the operating surgeon, and approximately 55% of
patients had a patch repair. There was no difference between the
percent of patients taking statin vs no statin who underwent a patch
repair.
To answer the second part of your question, I believe you were
asking in regard to statin therapy for carotid stenting?
Dr Chang. Besides putting a statin therapy on a patient with
carotid endarterectomy or stent procedure, how about putting
statin therapy on a population with a mild to moderate degree of
asymptomatic stenosis? By putting statins in that population with a
mild to moderate degree of disease, one can concentrate that statin
therapy may slow the progression of disease or even regress the
plaque. That’s my question.
Dr Brooke. Certainly I think that statin therapy would be
important for patients in the early stages of vascular disease. It
clearly should be part of the overall approach to risk factor modi-
fication in the vascular patient population. In medically managed
patients, for example, it has been shown that statin therapy can
reduce the incidence of primary stroke rates significantly. So I think
prophylactic statin therapy may theoretically prevent some patients
from ultimately going to surgery. That’s what some of the large
randomized trials have already demonstrated. But what’s less
known is what statin therapy will do for a surgical patient during
the perioperative period and how statins are working during the
perioperative period, and that was the purpose of this study.
Dr Richard Cambria (Boston, Mass). Aside from the cardiac
literature, which has shown statins to decrease the incidence of
recurrent infarction and prolong life, it seems like you can’t pick up
a journal or go to a meeting these days without finding some new
wonderful effect. The group from the Brigham has told us that it
decreases leg vein graft stenosis. Last year at this meeting, Dr
LaMuraglia of our group showed that they clearly decreased recur-
rent carotid stenosis and increased survival. So I wonder if we
won’t soon be having a sign in our offices that says you must be on
this drug.
At any rate, I have two questions about your data. The first is
that the important difference in your groups was the symptomatic
status. So was the symptomatic status of the carotid entered into
your multivariate model?
And the second is, with the higher incidence of stroke in the
combined carotid and CABG patients, would the effect still hold if
they were subtracted out?
Dr Brooke. To answer your first question, yes, patients who
were symptomatic at the time of presentation were included in our
multivariate analysis. Statin therapy was still found to be indepen-
dently associated with the reduction in stroke and mortality, ad-
justing for that symptomatic status. But it was interesting to find
that patients who were on statins presented less frequently with
strokes.
To answer your second question, the decrease in stroke and
mortality was still significantly lower when combined CABG/CEA
patients were subtracted out.
Dr Phillip Puckridge (Hamilton, New Zealand). First, we
know that statins are effective in stabilizing plaques; did you see a
bigger difference in stroke rates between the symptomatic and the
asymptomatic patients because of the effect of statins?
Second, the literature suggests that you have to be compliant
with statin therapy for a long time before you get the reduction in
stroke risk. Did you look at the timing of the patients who were on
statins before they came to surgery and whether that made a
difference?
Dr Brooke. To answer your first question, we looked at
symptomatic status in the multivariate analysis and found that the
benefit of statins was independent of the symptomatic status.
To answer your second question, one of the limitations of the
study was not knowing exactly how long patients have been on
the statin medication before their operation occurred. In med-
ical patients, there have been several studies that have shown
that patients need to be on statins for a longer period of time.
Some people have said at least 3 months before you’d see an effect,
at least in terms of lipid lowering. In terms of the pleiotropic or
lipid-independent effects of statins, it’s a little bit unclear, but this
is certainly one of the issues that would need to be addressed in
further studies.
Dr J. Fernandes (Lisbon, Portugal). We know statins stabilize
carotid plaques, and I wonder if you could tell us if there was any
difference in the echographic characteristics of the carotid plaques
in those patients with statins and without statins and if there was
any difference in the percentage of echolucent plaques in these two
groups.
My second question would be related to the long-term effects
of statins on the incidence of cardiovascular events. Please elabo-
rate on this regarding your group of patients. Was there any
difference in the incidence of cardiovascular events in those two
groups of patients—the long-term results?
Dr Brooke. To answer your first question, we did look at the
percentage of plaques that were assessed radiographically to be
ulcerative plaques, and there was no significant difference between
groups. Approximately 10% of plaques were assessed to be ulcer-
ative.
In terms of your second question, you raise an excellent
consideration. Unfortunately, our study examined only the peri-
operative impact of statin use, and we do not have the long-term
follow-up of these patients.
Dr Michael Judd (Spokane, Washington). Was antiplatelet
therapy employed equally in both cohorts of your patients?
Dr Brooke. Yes, it was.
Dr Judd. Can you elaborate on the type of therapy used? Did
you use aspirin or Plavix?
Dr Brooke. Again, patient management was surgeon specific.
However, the vast majority of the patients were treated with
dextran postoperatively for 24 hours, and almost all patients were
continued on aspirin postoperatively. Moreover, there was not a
significant difference between the statin vs no-statin cohorts in
terms of the percentage of patients taking antiplatelet medication
preoperatively.
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McGirt et al have reviewed their collective experience with
more than 1500 carotid endarterectomies spanning 11 years and
have reported that the use of 3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitors (commonly referred to as statins)
independently reduced the incidence of perioperative death and
stroke. Despite the limitations of their nonrandomized, retrospec-
tive study, the results are fairly compelling and provide further
justification for the use of the statin agents. In other studies, the
statin agents have been shown to reduce perioperative mortality
after coronary artery bypass grafting, percutaneous coronary revas-
cularization, and noncardiac vascular surgery. Furthermore, they
have been shown to reduce the incidence of cerebrovascular events
in high-risk patients, reduce the progression of carotid atheroscle-
rosis, and improve graft patency after infrainguinal bypass. The
mechanisms responsible for these beneficial effects are likely mul-
tifactorial and include plaque stabilization and attenuation of
inflammatory mediators, in addition to the reduction of the serum
lipid levels. Although their use in many of these clinical settings
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awaits the appropriate randomized, controlled trials and level 1
evidence, the weight of the current evidence is fairly overwhelming
and clearly justifies their use, particularly given their relatively
minor side effects. Indeed, the American Heart Association/
American College of Cardiology Guidelines for Preventing Heart
Attack and Death in Patients With Atherosclerotic Cardiovascular
Disease recommend an aspirin, -blocker, angiotensin-converting
enzyme inhibitor, and lipid-lowering agent, although not specifi-
cally a statin agent. Unfortunately, a significant proportion our
patients do not satisfy these recommendations. It is incumbent
upon us, as health care providers for patients with atheroscle-
rotic vascular disease, to assume the responsibility for ensuring
that all patients are receiving the optimal combination of med-
ications in an attempt to alter the natural history of the under-
lying disease process, rather than to simply manage its compli-
cations.
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